Two structurally distinct inhibitors of glycogen synthase kinase 3 induced centromere positive micronuclei in human lymphoblastoid TK6 cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 643, Issue 1-2, 2008, Pages 29-35

  Mishima, Masayuki ^a   Tanaka, Kenji ^a   Takeiri, Akira ^a   Harada, Asako ^a   Kubo, Chiyomi ^a   Sone, Sachiko ^a   Nishimura, Yoshikazu ^a   Tachibana, Yukako ^a   Okazaki, Makoto ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aneugen; FISH; Glycogen synthase kinase 3; Inhibitor; Micronucleus test

Indexed keywords

AMINOPYRIMIDINE; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; MALEIMIDE; PYRIMIDINE DERIVATIVE;

ARTICLE; CELL FUNCTION; CENTROMERE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; MICRONUCLEUS TEST; MITOSIS SPINDLE; PRIORITY JOURNAL;

ANEUGENS; BLOTTING, WESTERN; CELL NUCLEUS; CENTROMERE; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MALEIMIDES; MICRONUCLEUS TESTS; MICROTUBULES; MITOTIC SPINDLE APPARATUS; PYRIMIDINES;

EID: 49049086680     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2008.06.001     Document Type: Article

References (45)

1. Cohen P. The hormonal control of glycogen metabolism in mammalian muscle by multivalent phosphorylation. Biochem. Soc. Trans. 7 (1979) 459-480
2. Frame S., and Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359 (2001) 1-16
3. Engel T., Hernandez F., Avila J., and Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. Neurobiol. Dis. 26 (2006) 5083-5090
4. Rask K., Nilsson A., Brannstron M., Carlsson P., Hellberg P., Jansen P.O., Hedin L., and Sundfeldt K. Wnt-signalling pathway in ovarian epithelial tumors: increased expression of β-catenin and GSK3β. Br. J. Cancer 89 (2003) 1298-1304
5. Shakoori A., Ougolkov A.V., Yu Z.W., Zhang B., Modarressi M.H., Billadeau D.D., Mai M., Takahashi Y., and Minamoto T. Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. 334 (2005) 1365-1373
6. Ougolkov A.V., and Billadeau D.D. Targeting GSK-3: a promising approach for cancer therapy. Future Oncol. 2 (2006) 91-100
7. Mazor M., Kawano Y., Zhu H., Waxman J., and Kypta R.M. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23 (2004) 7882-7892
8. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., and Billadeau D.D. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 65 (2005) 2076-2081
9. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., and Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110 (2007) 735-742
10. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee C.L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., and Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7 (2000) 793-803
11. Ring D.B., Johnson K.W., Henriksen E.J., Nuss J.M., Goff D., Kinnick T.R., Ma S.T., Reeder J.W., Samuels I., Slabiak T., Wagman A.S., Hammond M.-E.W., and Harrison S.D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52 (2003) 588-595
12. Alonso M., and Martinez A. GSK-3 inhibitors; discoveries and developments. Curr. Med. Chem. 11 (2004) 755-763
13. Balaraman Y., Limaye A.R., Levey A.I., and Srinivasan S. Glycogen synthase kinase 3β and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol. Life Sci. 63 (2006) 1226-1235
14. Cohen P., and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. 3 (2004) 479-487
15. Armstrong V.J., Muzylak M., Sunters A., Zaman G., Saxon L.K., Price J.S., and Lanyon L.E. Wnt/β-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor. J. Biol. Chem. 282 (2007) 20715-20727
16. Rowe M.K., Wiest C., and Chuang D.-M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev. 31 (2007) 920-931
17. Wakefield J.S., and Hicks R.M. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. 116 (2003) 637-646
18. Maijor L., Flajolet M., and Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25 (2004) 471-480
19. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 1 (2001) 21-32
20. Fourest-Lieuvin A., Peris L., Gacke V., Garcia-Saez I., Juillan-Binard C., Lantez V., and Job D. Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1. Mol. Biol. Cell 17 (2006) 1041-1050
21. Kupcho K., Somberg R., Bulleit B., and Goueli S.A. A homogeneous, nonradioactive high-throughput fluorogenic protein kinase assay. Anal. Biochem. 317 (2003) 210-217
22. Eglen R.M. Enzyme fragment complementation: a flexible high throughput screening assay technology. ASSAY Drug Dev. Technol. 1 (2002) 97-104
23. Kirch-Volders M., Sofuni T., Aardema M., Albertini S., Eastmond D., Fenech M., Ishidate Jr. M., Kirchner S., Lorge E., Morita T., Norppa H., Surralles J., Vanhauwaert A., and Wakata A. Report from the in vitro micronucleus assay working group. Mutat. Res. 540 (2003) 153-163
24. Guo Z., Dose M., Kovalovsky D., Chang R., O'neil J., Look A.T., von Boehmer H., Khazaie K., and Gounari F. β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 109 (2007) 5463-5472
25. Tighe A., Ray-Sinha A., Staples O.D., and Taylor S.S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol. 8 (2007) 34
26. Mandelkow E.-M., Drewes G., Biernat J., Gustke N., Lint J.V., Vandenheede J.R., and Mandelkow E. Glycogen synthase kinase-3 and Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314 (1992) 315-321
27. 404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. J. Neurochem. 61 (1993) 1742-1747
28. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., and Imahori K. Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325 (1993) 167-172
29. Goold R.G., Owen R., and Gordon-Weeks P.R. Glycogen synthase 3βphosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J. Cell Sci. 112 (1999) 3373-3384
30. Sanchez C., Perez M., and Avila J. GSK3 beta-mediated phosphorylation of the microtubule-associated protein 2C(MAP2C) prevents microtubules bonding. Eur. J. Cell Biol. 79 (2000) 252-260
31. Alonso A.C., Zaidi T., Grundke-Iqbal I., and Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 5562-5566
32. Alonso A.C., Grundke-Iqbal I., and Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2 (1996) 783-787
33. Sarkissian M., Mendez R., and Richter J.D. Progesterone and insulin stimulation of CPEB-dependent polyadenylation is regulated by Aurora A and glycogen synthase kinase-3. Genes Dev. 18 (2004) 48-61
34. Roghi C., Giet R., Uzbekov R., Morin N., Chartrain I., Le Guellec R., Couturier A., Doree M., Philippe M., and Prigent C. The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. J. Cell Sci. 111 (1998) 557-572
35. Garrett S., Auer K., Compton D.A., and Kapoor T.M. hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division. Curr. Biol. 12 (2002) 2055-2059
36. Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., and Saya H. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. 278 (2003) 51786-51795
37. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., and Taylor S.S. Validating Aurora B as an anti-cancer drug target. J. Cell Sci. 119 (2006) 3664-3675
38. Alonso A.C., Grundke-Iqbal I., Barra H.S., and Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 298-303
39. Dehmelt L., and Halpain S. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6 (2005) 204.1-1204.1.
40. Shiina N., and Tsukita S. Regulation of microtubule organization during interphase and M phase. Cell Struct. Funct. 24 (1999) 385-391
41. Chapin S.J., and Bulinski J.C. Non-neuronal 210 × 10(3) Mr microtubule-associated protein(MAP4) contains a domain homologous to the microtubule-binding domains of neuronal MAP2 and tau. J. Cell Sci. 98 (1991) 27-36
42. Moreno F.J., Medina M., Perez M., Garcini E.M., and Avia J. Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparine (or tubulin). FEBS Lett. 372 (1995) 65-68
43. Wang J., Wu Q., Smith A., Grundke-Iqbal I., and Iqbal K. τ is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 436 (1998) 28-34
44. Mammalian Gene Collection Program Team, Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences, Proc. Natl. Acad. Sci. 99 (2002) 16899-16903.
45. Aardema M.J., Albertini S., Anri P., Henderson L.M., Kirch-Volders M., Mackay J.M., Sarrif A.M., Stringer D.A., and Taalman R.D.F. Aneuploidy: a report of an ECETOC task force. Mutat. Res. 410 (1998) 3-79